UBS Group’s ProShares Ultra CRCL CRCA Stock Holding History

UBS Group’s Portfolio CRCA Stock Details CRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.3K	Buy	+2,600	New	+$100K	﹤0.01%	7819
2026 Q1	–	Sell	-140	Closed	-$5.64K	–	11681
2025 Q4	$5.64K	Buy	+140	New	+$12K	﹤0.01%	8651

Other funds holding CRCA

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return

HCM

Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

UBS Group's CRCA Position: Q2 2026 in Review

UBS Group opened a new position in ProShares Ultra CRCL (CRCA) in Q2 2026: 2,600 shares worth $33.3K. The stake represents ﹤0.01% of the portfolio and ranks #7819 among its holdings. This is a return to the name: UBS Group previously reported a position in CRCA as recently as Q4 2025.

UBS Group first reported a position in CRCA in Q4 2025 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold CRCA as of Q2 2026.

UBS Group held 2,600 shares of ProShares Ultra CRCL worth $33.3K as of Q2 2026.
ProShares Ultra CRCL was a new UBS Group position in Q2 2026.
ProShares Ultra CRCL made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7819 holding.
UBS Group first reported a position in ProShares Ultra CRCL in Q4 2025 and has held it in 2 quarters since.
7 funds tracked by Wall St. Rank held ProShares Ultra CRCL as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.